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Abstract
Background & Aims: alterations of vascular endothelium play an important role in the development of cardiovascular diseases, the 
occurrence of liver cirrhosis and the progression of its complications. Little is known about the impact of the endothelial nitric oxide 
synthase (eNOS) gene mutations on the development of cardiovascular disease in patients with liver cirrhosis. The aim of the study was 
to investigate the possible association of the T894G gene polymorphism of eNOS with biochemical, cytokine blood indices, structural 
and functional parameters of heart in patients with nonviral liver cirrhosis. 
Methods: Investigation of eNOS gene polymorphism (T894G) was performed in 50 patients with nonviral liver cirrhosis and in 10 
healthy volunteers. Furthermore, biochemical blood analysis, estimations of tumor necrosis factor-α, transforming growth factor-β1, 
interleukin-4, atrial natriuretic propeptide (proaNP) plasma levels, echocardiographic studies were performed.
Results: It was established that the presence of T-allele of eNOS gene in patients with liver cirrhosis was associated with increased 
activity of aspartate aminotransferase, higher plasma content of proaNP, larger left atrium diameter and increased left ventricular 
myocardium mass. In males with liver cirrhosis, T-allele was also associated with increased left ventricular myocardium mass index 
compared with patients with GG-genotype.
Conclusion: The presence of T-allele of eNOS gene in patients with nonviral liver cirrhosis is associated with occurrence of more 
severe cardiovascular alterations.
Immunogastroenterology 2013; 2:68-75
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Introduction
Alterations of vascular endothelium play an important role in 
the development of cardiovascular diseases,1,2 the occurrence of 
liver cirrhosis and the progression of its complications, such as 
portal hypertension.3 Endothelial nitric oxide synthase (eNOS) 
producing nitric oxide (NO) plays a key role in the regulation 
of vascular tone, detoxification of superoxide anion radicals, 
inhibition of platelet aggregation, leukocyte adhesion and 
proliferation of smooth muscle fibers.4
The relationship between T894G, 4b/, T786C polymorphism 
of eNOS gene and the risk of ischemic heart disease have 
been actively investigated.5 It has been postulated that the 
E298D polymorphism of the eNOS gene has an impact on the 
development of heart stroke in the Japanese, British, Germans 
and Americans. In other nationalities (Koreans, Austrians, 
French, Irish, Dutch and Chileans), this relationship is not fixed; 
Greek studies have shown controversial results.6-9 It is also found 
that the E298D polymorphism of this gene is an independent risk 
factor for left ventricular hypertrophy in hypertensive patients.10 
In the Korean population, a significantly higher frequency of TT 
genotype of eNOS gene in patients with coronary atherosclerosis 
was revealed compared with healthy controls.11 The relationship 
of the T894G polymorphism variants of the eNOS gene with 
hyperhomocysteinemia has been established, being one of the 
risk factors for ischemic heart disease. In particular, among the 
citizens of Tunisia, ischemic heart disease patients, TT genotype 
of the eNOS gene and hyperhomocysteinemia led to a more 
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progressive course of the disease.12 In spite of fundamental 
investigation on how the eNOS gene polymorphism influences 
the development of various cardiovascular diseases, the 
association of gene polymorphism and liver pathology are not as 
yet fully elucidated.
Analyzing the literature on the test questions, the role of the 
eNOS gene in the development and progression of liver disease13,14 
was found. Increased intrahepatic vascular resistance in patients 
with liver cirrhosis is accompanied by decreased activity of eNOS 
and is enhanced by the accession of inflammation.15 In patients 
with liver cirrhosis, complicated with portal hypertension, a 
decrease in the activity of eNOS seems to cause decreased blood 
flow in the intrahepatic vessels.13,15
In this respect, little is known about the impact of genetic 
mutations, including eNOS gene polymorphism in the development 
of cardiovascular disease in patients with liver cirrhosis. Detailed 
and in-depth study of these issues is a precondition for optimizing 
therapeutic treatment in referred patients.
Considering the aforementioned data, the aim of the study 
was to investigate the possible association of T894G gene 
polymorphism of eNOS with the biochemical and cytokine blood 
parameters, structural and functional parameters of the heart in 
patients with nonviral liver cirrhosis.
Patients and methods
Investigation of eNOS gene polymorphism (T894G) was 
performed in 50 patients with nonviral liver cirrhosis and in 
10 healthy volunteers. The predominant etiologic factor in 
the development of liver cirrhosis in 41 patients (82.0%) was 
alcohol abuse. In 9 patients (18.0%), the main etiologic cause 
of the liver cirrhosis was a long-term professional contact with 
industrial hepatotoxic agents, including gasoline, pesticides, 
varnish, etc.
Blood samples were obtained in the morning, before meal 
from antecubital vein in the first day of hospitalization until the 
appointment of treatment. As an anticoagulant, 5% solution of 
disodium salt ethylenediaminetetraacetate was used. The study 
protocol was in accordance with the revised Helsinki Declaration 
(2008) and was approved by the local ethics committee. Written 
informed consent was obtained by all participants.
The inclusion criterion for patients in the study was diagnosis 
of liver cirrhosis of toxic and alcoholic etiology.
Exclusion criteria comprised: hepatitis B- and C-associated liver 
cirrhosis; autoimmune liver cirrhosis; liver fibrosis as a result of 
cardio-vascular insufficiency; liver cirrhosis of C class severity due 
to Child-Pugh criteria; hemochromatosis; severe cardio-vascular 
diseases (heart stroke, atrial fibrillation, rheumatic or congenital 
heart disease, heart failure III-IV functional class (NYHA)); 
connective tissue diseases (rheumatoid arthritis, systemic lupus 
Table 1. Primer sequences, restriction enzyme and allele calling for eNOS SNPs
SNP Restriction enzyme Primers Primer sequences (5’-3’) Allele calling (size of fragments, bp)
894T>G 
(rs1799983)
BanII Forward 5–ATGAAGGcAGGAGAcAGT GGATGG –3’ T: 250 bp; 
G: 160, 90 bpReverse 5’– ccAGTcAATcccTTTGGT GcTcA– 3’
eNOS, endothelial oxide synthase.
erythematosus, systemic sclerosis) and patients who refused to 
participate in the study protocol. Hepatitis B and C were excluded 
by polymerase chain reaction (PCR). Hemochromatosis was 
excluded by investigation of serum ferritin level and iron content 
in blood.
Diagnosis of liver cirrhosis was made by a combination of 
both clinical (patient history, signs of portal hypertension) and 
laboratory investigations (abnormal liver function tests, ultrasound 
findings of cirrhosis or endoscopic findings of varices).16,17
The degree of severity of liver cirrhosis was assessed by the 
Child-Pugh criteria.18,19 Based on these criteria, 21 patients had 
class A and 29 patients class B severity of liver cirrhosis.
To study the alleles of polymorphic sites T894G in eNOS 
gene, genomic DNA was identified from peripheral blood 
leukocytes with subsequent amplification of polymorphic sites 
using PCR with the help of programmable amplifier “Amply-
4L” (“Biokom”, Russia), with individual temperature program 
primers for the studied gene. The calculated positions of primers 
on the chromosome and their oligonucleotide sequence are 
given in table 1.
In order to discriminate alleles of the eNOS gene restriction 
endonucleases Ban II (Eco241) “Fermentas®” (USA) were used. 
PCR products were analyzed by electrophoresis in 3% agarose gels 
in the presence of tris-borate buffer concentrated with ethidium 
bromide. Fragments were visualized with ultraviolet emitter 
in the presence of the molecular weights marker 100-1000 bp 
(“SybEnzym”, Russia).
Electrophoregram amplification products are shown in 
figure 1. For eNOS gene in the presence of position 894 of exon 
7-guanidine, amplifier, which contained 250 base pairs, was 
splintered by restrictase Ban II (Eco 241) into two fragments 90 
and 160 nucleotide pairs. In case of replacement of G894 → T 
restriction site for Ban II was lost.
Selection of primer sequences and PCR analysis were performed 
by the standard methods, used worldwide.20,21
All of the patients and healthy volunteers underwent general 
complex clinical, laboratory and instrumental diagnostic 
investigations. Biochemical studies were performed on blood 
biochemical analyzer “Accent-200” (“Cormay SA”, Poland). The 
range of indicators of biochemical blood analysis included: total 
bilirubin and its fractions, cholesterol, triglycerides, uric acid, total 
protein and albumin, urea, creatinine, plasma enzyme activity 
[aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), lactate dehydrogenase (LDH), gamma-glutamyl 
transferase (GGT), alkaline phosphatase (AP)]. Cytokine profile 
parameters were measured by ELISA analyzer “Statfax 303+” 
(USA). Tumor necrosis factor (TNF)-α was determined using 
enzyme immunoassay that involved a set of reagents (Diaclone); 
for transforming growth factor (TGF)-β
1
 a commercial kit was 
used (Bender MedSystems GmbH), as also for interleukin 
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(IL)-4 (Diaclone), and atrial natriuretic propeptide (proANP) 
(Biomedica).
Echocardiographic studies were performed using ultrasound 
diagnostic system “En Visor HDS” (“Philips Ultrasound System”, 
USA) with the definition of structural and functional parameters by 
the Asmi & Walsh method.22 Calculation of cardiohemodynamics 
was conducted including: the left atrium (LA) diameter, the right 
ventricle diameter, the end-systolic and end-diastolic dimension 
of the left ventricle, interventricular septum thickness in systole 
and diastole, the thickness of the left ventricle posterior wall in 
systole and diastole. For each patient, values of ejection fraction, 
end-diastolic volume and end-systolic volume were calculated. 
Left ventricular myocardium mass (LVMM) was determined by 
the Devereux & Reichek formula as modified by the American 
Society of Echocardiography.23,24
LVMM index (LVMMI) was calculated using the formula: 
LVMMI (g/m²)=LVMM / BSA, where BSA, body surface area 
(m²).
In turn, BSA was calculated by the DuBois formula.25 Left 
ventricular hypertrophy was diagnosed according to the guidelines 
for the management of arterial hypertension (2007).26 Based 
on these recommendations, left ventricular hypertrophy was 
considered if LVMMI was increased; for men >125 g/m², while 
for women >110 g/m². 
Statistical analysis
Statistical processing of the data was performed by a computer 
program PAST Version 2.05.27 To determine the type of data 
distribution, comparing the arithmetic mean, median and 
mode, and Wilcoxon-Shapiro test were used. To determine the 
statistical differences between two independent groups Mann-
Whitney test and in case of three or more independent groups 
the Kruskal-Wallis test were applied. Analysis of qualitative data 
Figure 1. Electrophoregram of human DNA PCR products amplification of 
endothelial nitric oxide synthase (eNOS) 894T>G gene polymorphism. L: 
GeneRulerTM 100 bp DNA Ladder (1000-100 bp); G allele: 160, 90 bp; T allele: 
250 bp; lines 1-4, 6-8: heterozygous TG variant; lines 5, 9: homozygous GG 
variant.
(categorical variables) was assessed using chi-square test (χ2). 
Hardy-Weinberg equilibrium was calculated to describe the 
relationship between gene frequency and genotype frequency, 
comparison of allele frequencies with 1 degree of freedom and 
genotypes between the groups and control with 2 degrees of 
freedom. Multiple linear regression analysis was performed. The 
association between LVMMI, proANP, age and AST, gender, LA, 
T allele, LVMMI, LVMM were tested using odds ratio (OR), 
risk ratio (RR) with 95% confidence interval (CI). Correlation 
between variables was calculated by means of linear regression 
analysis. Reliable probability of error was considered less than 
5% (p<0.05).28,29
Results 
Polymorphism (T894G) of eNOS gene was studied in 50 patients 
(34 men; mean age 54.1±9.9 years) with nonviral liver cirrhosis 
and 10 healthy volunteers (control group) (7 men; mean age 
52.4±10.4 years). The distribution of genotypes of the eNOS gene 
polymorphism is shown in table 2.
Among patients with liver cirrhosis 2 patients (4.0%) had 
TT genotype; 32 patients (64.0%) had TG genotype; and 16 
patients (32.0%) had GG genotype. T-allele carriers were 18 
persons (36.0%), and G-allele carriers were 32 persons (64.0%). 
In the group of healthy volunteers, homozygous carriers T-allele 
were none, 70.0% of surveyed individuals in this group were 
heterozygotes, 30.0% homozygous carriers of G-allele, which 
probably is not different from the distribution of genotypes 
among patients with liver cirrhosis. The distribution of all alleles 
and genotypes of analyzed genes were determined within the 
Hardy-Weinberg equilibrium. 
The association of biochemical blood parameters of patients 
with liver cirrhosis with T894G polymorphism of the eNOS gene 
are presented in table 3. Due to the fact that the number of carriers 
of the unfavorable TT-genotype was limited (n=2), there was a 
need to analyze indicators for the presence of abnormal T-allele. 
In patients with T-allele, AST activity was significantly higher at 
27.4% (p<0.05) than in patients with the GG-genotype. Also, in 
patients with T-allele a significantly greater urea plasma level by 
33.3% (p<0.05) and creatinine plasma level by 22.2% (p<0.05) 
than in patients with GG-genotype was revealed. For the rest of 
the blood biochemical parameters differences between genotypes 
were not statistically significant.
In patients with T-allele, the concentration of proANP in 
plasma by 89.2% (p<0.05) was significantly higher compared 
with the cytokine level in patients with liver cirrhosis with GG-
genotype, which was associated with more severe manifestations 
of cardiovascular alterations: more frequent complaints of chest 
pain, discomfort in epicardium, shortness of breath, and in some 
patients the development of heart failure of IIA-IIB stage and 
edema (Table 4). 
Heart rate, systolic and diastolic blood pressure between 
genotypes of the eNOS gene carriers did not differ significantly 
(Table 5). Only a tendency to tachycardia was noted in patients 
with liver cirrhosis compared with healthy volunteers.
Structural and functional parameters of the heart in patients 
with liver cirrhosis depending on the T894G polymorphism of 
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Table 2. Distribution of the eNOS gene polymorphism (T894G) in patients with liver cirrhosis and healthy individuals
eNOS gene genotype Patients with liver cirrhosis (n=50) Healthy volunteers (n=10)
Absolute quantity, n Percentage Absolute quantity, n Percentage
TT 2 4.0% 0 0.0%
TG 32 64.0% 7 70.0%
GG 16 32.0% 3 30.0%
eNOS, endothelial oxide synthase.
Table 3. Biochemical blood parameters in patients with liver cirrhosis according to T894G polymorphism of the eNOS gene
Plasma level Healthy volunteers, n=10 Patients with liver cirrhosis, n=50
T-allele carriers, n=34 GG-genotype carriers, n=16
Total bilirubin, mkmol/L (N=5.0-20.5) 12.38±2.89 50.80±9.58* 54.62±8.51*
Direct bilirubin, mkmol/L (N=0.5-5.0) 4.90±0.54 14.30±2.90* 15.56±2.43*
cholesterol, mmol/L (N=3.1-6.8) 4.51±0.24 4.13±0.39 3.75±0.23*
Triglycerides, mmol/L (N=0.4-1.8) 1.44±0.18 1.29±0.18 1.11±0.10*
Albumin, g/L (N=35-50) 43.43±1.36 32.26±1.45* 34.56±1.81*
Total protein, g/L (N=65-85) 68.67±1.02 69.39±1.35 69.40±1.32
Urea, mmol/L (N=2.4-8.3) 5.13±0.43 6.65±0.64** 4.99±0.37
creatinine, mkmol/L (N=40-110) 89.20±2.96 99.74±9.48** 81.63±6.57
Aspartate aminotransferase, units of action/L (N<37) 18.00±0.90 74.48±8.96*/** 58.44±4.68*
Alanine aminotransferase, units of action/l (N<32) 21.17±2.57 43.16±5.00* 38.31±5.46*
Lactate dehydrogenase, units of action/L (N=210-420) 273.33±25.05 430.78±27.28* 401.88±32.11*
Alkaline phosphatase, units of action/L (N=42-141) 62.29±5.75 129.88±8.71* 108.69±7.30*
Gamma-glutamyl transferase, units of action/L (N=10-50) 29.57±6.13 126.00±27.61* 110.94±25.45*
*: significance of differences (p<0.05) compared with the figures in the group of healthy people; **: significance of differences (p<0.05) compared with rates in 
patients with the GG-genotype. eNOS, endothelial oxide synthase.
Table 4. Cytokine plasma content in patients with liver cirrhosis depending on the T894G polymorphism of the eNOS  gene
Plasma level Healthy volunteers, n=10 Patients with liver cirrhosis, n=50
T-allele carriers,  n=34 GG-genotype carriers, n=16
Interleukin-4, pg/mL 1.85±0.17 0.84±0.14 0.76±0.14
Tumor necrosis factor-α, pg/mL 32.82±2.40 62.41±7.00* 70.49±10.08*
Transforming growth factor-β1, pg/mL 323.18±83.94 406.29±47.73 477.85±82.10
Atrial natriuretic propeptide, nmol/L 0.32±0.04 2.27±0.34*/** 1.20±0.15*
*: significance of differences (p<0.05) compared with the figures in the group of healthy people; **: significance of differences (p<0.05) compared with rates in 
patients with the GG-genotype. eNOS, endothelial oxide synthase.
Table 5. Heart rate, systolic and diastolic blood pressure depending T894G polymorphism of the eNOS gene
Investigated parameter Healthy volunteers, n=10 Patients with liver cirrhosis, n=50
T-allele carriers, n=34 GG-genotype carriers, n=16
Heart rate 72.29±0.52 84.50±1.64* 84.00±3.41*
Systolic arterial blood pressure 123.57±1.80 123.38±2.45 122.19±3.56
Diastolic arterial blood pressure 77.14±1.84 77.94±1.25 73.75±1.80
*: significance of differences (p<0.01) compared to rates in the group of healthy people. eNOS, endothelial oxide synthase.
the eNOS gene are presented in table 6.
The LA diameter was larger significantly in T allele carriers 
with liver cirrhosis, than in homozygous G allele patients by 
13.6% (p<0.01). Also, in T-allele carriers, there was a higher 
left LVMM by 19.5% (p<0.01) and LVMMI in males at 12.2% 
(p<0.05), than in patients with liver cirrhosis with GG-genotype. 
Multiple linear regression analysis, RRs, and ORs estimated 
for analyzed variables are presented in table 7. LVMMI was 
significantly related to AST (RR=1.70, 95% CI=1.17-2.47, 
p=0.002), LA (RR=2.53, 95% CI=0.94-5.85, p=0.02) and 
proANP (RR=2.0, 95% CI=1.08-3.72, p=0.002), whereas 
proANP was reliably related to LVMMI (RR=5.16, 95% 
CI=1.46-18.18, p=0.0001) and T allele presence (RR=2.35, 95% 
CI=0.95-5.85, p=0.02). Age and gender however were not related 
to either LVMMI or proANP in liver cirrhosis patients. T allele 
of eNOS gene is considered as independent additional predictor 
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Table 6. Structural and functional indices of the cardiovascular system in patients with liver cirrhosis depending on the T894G polymorphism of the eNOS gene
Investigated parameter Healthy 
volunteers, n=10
Patients with liver cirrhosis, 
n=50
T-allele carriers, n=34 GG-genotype carriers, n=16
Aorta diameter (cm) 3.39±0.12 3.44±0.10 3.57±0.17
Left atrium diameter (cm) 3.92±0.14 4.52±0.09*/** 3.98±0.08
End diastolic dimension (cm) 5.26±0.12 5.48±0.15 5.12±0.21
End systolic dimension (cm) 3.41±0.09 3.63±0.11* 3.50±0.19
End diastolic volume (mL) 133.14±7.03 147.60±8.90 125.83±11.04
End systolic volume (mL) 51.71±3.34 56.27±4.04 51.67±6.52
Thickness of the posterior wall of the left ventricle in diastole (cm) 1.07±0.06 1.24±0.02* 1.21±0.04*
Thickness of the posterior wall of the left ventricle in systole (cm) 1.54±0.08 1.64±0.04 1.72±0.05
The thickness of the intraventricular septum in diastole (cm) 1.11±0.06 1.26±0.04* 1.22±0.04*
The thickness of the intraventricular septum in systole (cm) 1.25±0.04 1.39±0.04* 1.33±0.06*
Right ventricular diameter (cm) 2.11±0.04 2.35±0.07* 2.31±0.14*
Ejection fraction (%) 63.33±0.40 60.21±1.06* 60.60±1.17*
Left ventricular myocardium mass (mg) 213.94±20.94 302.86±20.57*/** 253.40±21.58*
Left ventricular myocardium mass index (mg/m²) male 123.81±12.00 155.33±11.41*/** 138.39±7.06
female 103.97±10.08 135.79±8.79* 120.29±11.09*
*: significance of differences (p<0.05) compared to rates in the group of healthy people; **: significance of differences (p<0.05) compared with rates in patients 
with the GG-genotype. eNOS, endothelial oxide synthase.
Table 7. Association of diagnostic variables with left ventricle hypertrophy, ProANP and age in liver cirrhosis patients
Variables β p RR OR 95% CI RR p
LVMMI Age 0.05 0.58 1.04 1.08 0.80-1.28 0.65
Sex -0.09 0.41 0.91 0.53 0.73-1.13 0.49
AST 0.22 0.03 1.70 26.25 1.17-2.47 0.002
LA -0.28 0.02 2.53 12.5 0.94-5.85 0.02
T allele -0.18 0.08 2.92 12.5 0.88-9.67 0.04
ProANP 0.61 0.00 2.0 – 1.08-3.72 0.002
R2=0.8711736; ε=18.395; F=18.89042; df =5.30; p<0.0000 
ProANP Age -0.07 0.52 0.98 0.92 0.78-1.25 0.59
Sex -0.10 0.38 1.10 1.88 0.88-1.37 0.36
AST -0.21 0.07 0.59 0.04 0.40-0.85 0.02
LA 0.21 0.07 0.42 0.08 0.17-1.06 0.02
T allele 0.30 0.05 2.35 12.5 0.95-5.85 0.02
LVMMI 0.77 0.00 5.16 67.5 1.46-18.18 0.0001
LVMM 0.01 0.94 1.97 8.75 0.93-4.18 0.058
R2=0.83485435; ε=0.45014; F=17.82602; df=4.31; p<0.0000
Age AST -0.08 0.86 1.35 7.92 0.97-1.86 0.075
LA 0.37 0.027 2.96 13.75 0.90-9.77 0.02
T allele 0.03 0.86 1.05 1.22 0.74-1.48 0.53
LVMMI 0.10 0.53 1.92 6.75 0.88-4.67 0.055
LVMM 0.19 0.36 1.93 7.50 0.90-4.13 0.05
ProANP 0.04 0.81 – – – –
R2=0.37; ε=12.06; F=5.35; df=1.34; p=0.027
β: standard regression coefficient; R2: multiple coefficient  of determination; ε: Standard error of estimate; RR, risk ratio; OR, Odds Ratio; df, degrees of freedom; 
95% CІ RR, confidence interval of Risk Ratio; LVMM, left ventricular myocardium mass; LVMMI, left ventricular myocardium mass index; proANP, atrial 
natriuretic propeptide. 
of left ventricle hypertrophy (RR=2.92, 95% CI=0.88-9.67, 
p=0.04) and heart failure appearance (RR=2.35, 95% CI=0.95-
5.85, p=0.02). Age was associated in liver cirrhosis patients only 
with an increased risk for LA diameter (RR=2.96, 95% CI=0.90-
9.77, p=0.02).
Discussion 
We conducted a detailed analysis of the relation of biochemical 
blood parameters, cytokine blood profile, structural and functional 
parameters of the heart with the T894G polymorphism eNOS 
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gene. In our own patients with liver cirrhosis, T-allele carriers 
showed a significantly higher activity of AST and increased 
concentrations of proANP, which are markers of cytolytic 
process in myocardium and the development of cardiovascular 
insufficiency compared with GG-genotype carriers.30,31 Thus, 
the above might indicate a greater tendency of these processes to 
develop in patients with T-allele of eNOS gene. In patients with 
T-allele such changes were associated with a significant increase 
in the LA diameter by 13.6% (p<0.01) and LVMM by 19.5% 
(p<0.01). In males T-allele carriers LVMMI was also increased 
by 12.2% (p<0.05) compared with males with GG-genotype. 
In patients with liver cirrhosis, T-allele carriers had significantly 
higher urea plasma level by 33.3% (p<0.05) and creatinine 
plasma level by 22.2% (p<0.05) compared with patients with 
the GG-genotype. This may indicate that in T-allele carrier 
cirrhotic patients, kidney and cardiovascular function is more 
severely impaired32,33 than in GG-genotype patients. Thus, we 
hypothesized that T allele presence in liver cirrhosis patients 
may predispose to more severe damage of the target-organs of 
cardiovascular system with development of latent heart failure 
and can be considered as an early diagnostic marker of vascular 
injury in these patients.
Gene eNOS, discovered in 1993, is localized on chromosome 
7q35-36, occupying interval 4.4 kB genomic DNA, and consists 
of 26 exons encoding the 135-kDa protein containing 1203 
amino acids. Three clinically important polymorphisms of eNOS 
have been studied, with an established association with a number 
of cardiovascular diseases: single nucleotide polymorphisms, 
one in the promoter region (T-786C), and the other in exon 7 
(T894G), with variable number tandem repeats in intron 4.34-36 
It was found that the only mutation of the eNOS gene, which 
leads to a change in the amino acid sequence of protein structure, 
is T894G (rs1799983) variant in which guanine is replaced by 
thymine in exon 7, which leads to the substitution of glutamate 
(E) to aspartate (D) (E298D) at codon 298.37 
It is well known that vascular endothelial dysfunction plays an 
important role in the development of cardiovascular diseases,1,2 the 
occurrence of liver cirrhosis and progression of its complications, 
such as portal hypertension.3 The background for endothelial 
dysfunction serves an imbalance between local generation and 
decay of vasoactive substances, among which the NO plays the 
key role.4,7,37,38 In experimental models of chronic parenchymal 
liver disease complicated by portal hypertension, increased activity 
of nitric oxide synthase and increased concentrations of NO were 
observed,39 but the mechanisms of these changes remain vaguely 
understood. eNOS gene modulates the activity of the enzyme eNOS, 
that, in turn, synthesizes NO by reaction converting L-arginine to 
L-citrulline, which involves the transfer of five electrons by NAD(P)
H. eNOS utilizes L-arginine and molecular oxygen and requires 
the cofactors NAD(P)H, flavin adenine dinucleotide, flavin 
mononucleotide, and (6R-) 5,6,7,8-tetrahydrobiopterin.40 Along 
with the mentioned mechanism of eNOS activity regulation, 
calmodulin and calcium intracellular level play an important 
role in these processes.41,42 Bradykinin, histamine, serotonin 
are agents that increase intracellular calcium level by increasing 
calcium input from the outside or by stimulating calcium 
mobilization from intracellular depots, can activate eNOS, and 
respectively NO synthesis.43,44 In addition to direct regulation 
of eNOS, NO availability is also dependent on the activity of 
oxygen free radicals generation, and an increase in superoxide 
anion can be determinant in reducing NO availability.45,46 eNOS, 
mostly expressed in endothelial cells, induces vasodilation, 
controls blood pressure, and has various vasoprotective and 
anti-atherosclerotic effects.40,45 Thus, the production of NO 
is regulated by direct modeling of eNOS gene expression and 
enzyme activity of eNOS or indirectly through changes in the 
activity of endogenous cofactors and inhibitory molecules.47,48
Therefore, our study confirms the results of other authors13,14 
which postulate the influence of eNOS genotype to the liver 
cirrhosis, moreover we investigate that polymorphism of 
eNOS gene is involved in the development of cardiovascular 
complications in such patients. It was shown that in patients 
with liver cirrhosis with portal hypertension, a decreased activity 
of eNOS was recorded, which led to disturbances of intrahepatic 
bloodflow.13,15 However, there is a little information about the 
changes of central blood flow and condition of cardiovascular 
system in such patients. Together with echocardiac findings, 
plasma levels of proANP, a molecule which is one of the most 
undisputable markers of cardiovascular insufficiency,49,50 were 
increased in patients with liver cirrhosis. Moreover, it was found 
that T-allele carriers had significantly higher proANP plasma 
level compared with GG-genotype carriers, which correlated 
with structural changes of the heart: increased LA diameter and 
LVMM and LVMMI in males. To our knowledge, no relative 
clinical data exist, but similar changes were mentioned by Inserte 
et al. on rats, who found that portal hypertension associated to 
biliary cirrhosis induces marked left ventricle hypertrophy and 
increased myocardial NO synthesis due to increased eNOS 
expression.51
Potential limitations of the study are the small number of 
enrolled subjects together with the need for additional studies 
to determine the pathogenetic mechanisms by which the eNOS 
(T894G) genotypes influence the NO system.
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Summary Box
What is already known: 
•	 The polymorphism of the endothelial nitric oxide synthase (eNOS) gene is related with a higher risk of cardiovascular diseases.
•	 TT genotype of the eNOS gene is associated with more frequent development of coronary atherosclerosis, heart stroke and 
higher plasma content of homocysteine, which leads to a more severe course of ischemic heart disease.
•	 activity of eNOS enzyme is associated with changes in the intrahepatic blood flow and the severity of inflammation in liver 
parenchyma. Increased intrahepatic vascular resistance in patients with liver cirrhosis is accompanied by decreased activity of 
eNOS and is enhanced by the accession of inflammation. In patients with liver cirrhosis, complicated with portal hypertension, a 
decrease in the activity of eNOS causes decreased blood flow in the intrahepatic vessels.
What the new findings are:
•	 The presence of T-allele of eNOS gene in patients with liver cirrhosis is associated with increased activity of aspartate 
aminotransferase, higher content of atrial natriuretic propeptide in blood, increased left atrium diameter and left ventricular 
myocardium mass compared with patients with the GG-genotype.
•	 In male patients with liver cirrhosis, presence of T-allele was also associated with increased left ventricular myocardium mass 
index compared with patients with the GG-genotype.
•	 The presence of T-allele of eNOS gene in patients with nonviral liver cirrhosis is associated with more severe cardiovascular 
alterations.
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